bioAffinity Technologies, Inc. Common Stock earnings per share and revenue
On Nov 14, 2025, BIAF reported earnings of -4.74 USD per share (EPS) for Q3 25, missing the estimate of -2.75 USD, resulting in a -72.11% surprise. Revenue reached 1.45 million, compared to an expected 1.44 million, with a 0.47% difference. The market reacted with a -2.13% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 3 analysts forecast an EPS of -2.75 USD, with revenue projected to reach 1.58 million USD, implying an decrease of -41.98% EPS, and increase of 9.55% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
FAQ
What were bioAffinity Technologies, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, bioAffinity Technologies, Inc. Common Stock reported EPS of -$4.74, missing estimates by -72.11%, and revenue of $1.45M, 0.47% above expectations.
How did the market react to bioAffinity Technologies, Inc. Common Stock's Q3 2025 earnings?
The stock price moved down -2.13%, changed from $1.88 before the earnings release to $1.84 the day after.
When is bioAffinity Technologies, Inc. Common Stock expected to report next?
The next earning report is scheduled for Mar 30, 2026.
What are the forecasts for bioAffinity Technologies, Inc. Common Stock's next earnings report?
Based on 3
analysts, bioAffinity Technologies, Inc. Common Stock is expected to report EPS of -$2.75 and revenue of $1.58M for Q4 2025.